An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease

Trial Profile

An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs RG 7880 (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 29 Jan 2018 Planned number of patients changed from 45 to 90.
    • 16 Oct 2017 Planned End Date changed from 27 Oct 2017 to 7 Feb 2020.
    • 16 Oct 2017 Planned primary completion date changed from 27 Oct 2017 to 7 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top